221800 — U2Bio Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapHigh Flyer

Annual cashflow statement for U2Bio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-559	9,236	13,160	646	-2,840
Depreciation
Amortisation
Non-Cash Items	2,303	2,872	2,914	-3,443	624
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-976	72.8	7,444	-676	-392
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	1,374	12,751	24,406	-2,555	-1,731
Capital Expenditures	-347	-387	-1,142	-978	-353
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	1,411	-116	-35,544	34,183	-15,979
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	1,064	-503	-36,686	33,205	-16,333
Financing Cash Flow Items	—	—	—	-326	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-274	-265	-2,771	3,207	-737
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	2,164	11,983	-15,052	33,858	-18,801